Compare INFU & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INFU | XBIT |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.8M | 74.4M |
| IPO Year | 2005 | 2015 |
| Metric | INFU | XBIT |
|---|---|---|
| Price | $9.19 | $2.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 246.5K | 20.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 181.82 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $143,436,000.00 | N/A |
| Revenue This Year | $3.20 | N/A |
| Revenue Next Year | $7.31 | N/A |
| P/E Ratio | $181.70 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $5.43 | $2.09 |
| 52 Week High | $11.04 | $3.61 |
| Indicator | INFU | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.10 | 48.22 |
| Support Level | $8.57 | $2.35 |
| Resistance Level | $10.84 | $2.49 |
| Average True Range (ATR) | 0.55 | 0.06 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 50.91 | 42.86 |
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.